Related Experiment Videos
Pharmacologic review of thrombolytic agents
Abstract:
Thrombolytic therapy has significantly reduced the morbidity and mortality that was once associated with acute myocardial infarction. Because of the substantial benefits associated with this therapy, investigation has intensified in search of the optimal agent or agents. Five agents are currently being investigated individually and in various combinations to determine which agent(s) will outperform the others in terms of reperfusion, patency, mortality reduction, and clinical events. Two of the agents, t-PA and scu-PA, are considered fibrin selective, whereas the other three, streptokinase, urokinase and APSAC are nonselective. Whether this distinction provides substantial benefit is still not known. All of the FDA-approved agents (streptokinase, t-PA, and APSAC) have demonstrated survival benefit and will continue to be administered in AMI patients. In addition, the 1990s begins a new era that includes broadened selection criteria for AMI patients as well as expanding cardiovascular indications for thrombolytic therapy. The challenge to nurses is to improve and implement nursing care practices at the same rapid pace set by the medical discipline. This includes astute assessment and observational skills necessary to prevent and detect potential complications associated with thrombolytic therapy. Rapidly changing medical techniques mandate ongoing nursing research, which is needed to determine the most effective interventions in reducing complications associated with thrombolytic therapy and in promoting positive adaptive behaviors in the AMI patient. Thrombolytic therapy is an intervention for the 1990s, and nursing care is essential in maintaining the beneficial effects of this dynamic therapy.
Insights
Thrombolytic therapy significantly reduces deaths from acute myocardial infarction (AMI). Ongoing research seeks the best agents and nursing strategies to improve patient outcomes and manage complications effectively.
Area of Science:
- Cardiology
- Pharmacology
- Nursing Science
Background:
- Thrombolytic therapy has drastically improved outcomes for acute myocardial infarction (AMI).
- Current research focuses on identifying optimal thrombolytic agents and combinations for improved reperfusion, patency, and survival.
- The landscape of thrombolytic therapy is expanding with broader patient criteria and new cardiovascular indications.
Purpose of the Study:
- To evaluate the effectiveness of various thrombolytic agents in treating acute myocardial infarction.
- To compare fibrin-selective agents (t-PA, scu-PA) with non-selective agents (streptokinase, urokinase, APSAC).
- To highlight the critical role of nursing in managing patients undergoing thrombolytic therapy and preventing complications.
Main Methods:
- Investigation of five thrombolytic agents individually and in combination.
- Assessment of outcomes including reperfusion rates, arterial patency, mortality reduction, and clinical events.
- Focus on nursing interventions for complication detection and patient adaptation.
Main Results:
- FDA-approved agents (streptokinase, t-PA, APSAC) have demonstrated survival benefits in AMI patients.
- Fibrin selectivity of t-PA and scu-PA versus non-selective agents requires further investigation for clinical significance.
- Nursing care is identified as essential for maintaining therapeutic benefits and managing complications.
Conclusions:
- Thrombolytic therapy remains a cornerstone in managing acute myocardial infarction.
- Continued research is necessary to optimize agent selection and nursing interventions.
- Nursing vigilance and research are crucial for maximizing the benefits of evolving thrombolytic treatments.